SDF-1及其受体CXCR4在前列腺癌中的研究进展  

Research Progress of Chemokine SDF-1 and Its Receptor CXCR4 in Prostate Cancer

作　　者：赵立民 高伟兴[2] 

机构地区：[1]三河市燕郊人民医院外科,河北三河065201 [2]华北煤炭医学院附属医院泌尿外科,河北唐山063000

出　　处：《医学综述》2010年第12期1820-1822,共3页Medical Recapitulate

摘　　要：趋化因子基质细胞衍生因子1(SDF-1)及其受体CXCR4是趋化性细胞因子家族里的一个重要亚族,广泛存在于正常组织中。前列腺癌是目前最常见的一种男性泌尿系统肿瘤,多发生于50岁以上的男性。前列腺癌的发病率位于西欧国家男性恶性肿瘤的第二位,而病死率已排在男性恶性肿瘤患者的第一位。近几年来,由于我国男性居民饮食习惯、生活方式的改变,该病的发病率呈逐年上升的趋势。近年研究发现SDF-1及其受体CXCR4与前列腺癌的发生、转移等机制有着密切的关系。因此,进一步研究SDF-1/CXCR4通路的机制,可能对完善前列腺癌的发病机制及判断预后,甚至为前列腺癌的治疗提供重要的临床价值。Stromal cell-derived factor-1 and CXC chemokine receptor 4 are important substrates in chemokine family,widely existing in normal tissues.Prostate cancer（PCa）is one of the most common male urological tumors,occurring in men over 50.As the second most frequent malignant tumor in Western Europe,PCa comes in the first place in mortality.In recent years,due to the changes in Chinese life style and eating habits,the incidence of the disease shows an ascendant trend.It has been reported that SDF-1 and its receptor CXCR4 are closely associated with the development and metastasis of PCa.Therefore,the further investigation into the mechanism of SDF-1/CXCR4 pathway may be clinically valuable in the discovery of PCa pathogenesis,the prediction of prognosis and the treatment of PCa.

关 键 词：趋化因子 趋化因子受体 肿瘤 前列腺癌 

分 类 号：R737.25[医药卫生—肿瘤]